FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibro...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2017-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/5/1/17.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850195051930451968 |
|---|---|
| author | Stefan N. Symeonides Stephen M. Anderton Alan Serrels |
| author_facet | Stefan N. Symeonides Stephen M. Anderton Alan Serrels |
| author_sort | Stefan N. Symeonides |
| collection | DOAJ |
| description | Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy. |
| format | Article |
| id | doaj-art-b7a44e71555f482e9f0565d7367c8d14 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2017-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-b7a44e71555f482e9f0565d7367c8d142025-08-20T02:13:51ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262017-08-015110.1186/s40425-017-0217-6FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic CancerStefan N. Symeonides0Stephen M. Anderton1Alan Serrels2Aff2 0000 0004 1936 7988grid.4305.2Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular MedicineUniversity of Edinburgh EH4 2XR Edinburgh UKAff1 0000 0004 1936 7988grid.4305.2MRC Centre for Inflammation Research, The Queen’s Medical Research InstituteUniversity of Edinburgh EH16 4TJ Edinburgh UKCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UKImmunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.https://jitc.bmj.com/content/5/1/17.full |
| spellingShingle | Stefan N. Symeonides Stephen M. Anderton Alan Serrels FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer Journal for ImmunoTherapy of Cancer |
| title | FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer |
| title_full | FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer |
| title_fullStr | FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer |
| title_full_unstemmed | FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer |
| title_short | FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer |
| title_sort | fak inhibition opens the door to checkpoint immunotherapy in pancreatic cancer |
| url | https://jitc.bmj.com/content/5/1/17.full |
| work_keys_str_mv | AT stefannsymeonides fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer AT stephenmanderton fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer AT alanserrels fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer |